MicroRNAs in POI, DOR and POR

Luo, Jiali; Sun, Zhaogui

doi:10.1007/s00404-023-06922-z

Cited by 5 publications

(3 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is an increasing body of work detailing the expression of miRNAs in the ovaries of several species including humans using bioinformatics ( 300 ), and their potential use for treating various ovarian conditions particularly POI is being investigated, as reviewed in Ref. 301 . There is, however, considerable heterogeneity in the results of studies investigating miRNAs and other noncoding RNAs in human disease, such as in polycystic ovary syndrome ( 302 ), and while we acknowledge the importance of these molecules in ovarian/oocyte development, there is still much to clarify.…”

Section: Primordial Follicle Recruitment Into the Growing Poolmentioning

confidence: 99%

“…There is, however, considerable heterogeneity in the results of studies investigating miRNAs and other noncoding RNAs in human disease, such as in polycystic ovary syndrome ( 302 ), and while we acknowledge the importance of these molecules in ovarian/oocyte development, there is still much to clarify. Thus their contributions are not discussed here in detail but have been recently reviewed in the context of the human ovary ( 301 , 303 ).…”

Section: Primordial Follicle Recruitment Into the Growing Poolmentioning

confidence: 99%

See 1 more Smart Citation

Making a good egg: human oocyte health, aging, and in vitro development

Telfer

Grosbois

Odey

et al. 2023

Physiological Reviews

View full text Add to dashboard Cite

Mammalian eggs (oocytes) are formed during fetal life and establish associations with somatic cells to form primordial follicles that create a store of germ cells (the primordial pool). The size of this pool is influenced by key events during the formation of germ cells and by factors that influence the subsequent activation of follicle growth. These regulatory pathways must ensure that the reserve of oocytes within primordial follicles in humans lasts for up to 50 years, yet only approximately 0.1% will ever be ovulated with the rest undergoing degeneration. This review outlines the mechanisms and regulatory pathways that govern the processes of oocyte and follicle formation and later growth, within the ovarian stroma, through to ovulation with particular reference to human oocytes/follicles. In addition, the effects of aging on female reproductive capacity through changes in oocyte number and quality are emphasized, with both the cellular mechanisms and clinical implications discussed. Finally, details of current developments in culture systems that support all stages of follicle growth to generate mature oocytes in vitro, and emerging prospects for making new oocytes from stem cells are outlined.

show abstract

Section: Primordial Follicle Recruitment Into the Growing Poolmentioning

confidence: 99%

Section: Primordial Follicle Recruitment Into the Growing Poolmentioning

confidence: 99%

Making a good egg: human oocyte health, aging, and in vitro development

Telfer

Grosbois

Odey

et al. 2023

Physiological Reviews

View full text Add to dashboard Cite

show abstract

“…Micro-RNAs are short, 18–24 nucleotides long, non-coding RNAs, which regulate cell proliferation, differentiation and apoptosis ( 14 ). Their pathogenetic role in POI has been increasingly recognized over the last years, being involved in steroidogenesis, granulosa cell proliferation/apoptosis, autophagy and follicular development by regulating specific pathways, such as the PI3K/Akt/mTOR, TGFβ, mitogen-activated protein kinase (MAPK) and Hippo pathways ( 105 ). Many of these molecules have shown to be either upregulated or downregulated in models of POI and have been proposed as biomarkers ( 106 ).…”

Section: Micro-rnasmentioning

confidence: 99%

Biological therapies for premature ovarian insufficiency: what is the evidence?

Moustaki,

Kontogeorgi,

Tsangkalova

et al. 2023

Front. Reprod. Health

View full text Add to dashboard Cite

Premature Ovarian Insufficiency (POI) is a multi-factorial disorder that affects women of reproductive age. The condition is characterized by the loss of ovarian function before the age of 40 years and several factors have been identified to be implicated in its pathogenesis. Remarkably though, at least 50% of women have remaining follicles in their ovaries after the development of ovarian insufficiency. Population data show that approximately up to 3.7% of women worldwide suffer from POI and subsequent infertility. Currently, the treatment of POI-related infertility involves oocyte donation. However, many women with POI desire to conceive with their own ova. Therefore, experimental biological therapies, such as Platelet-Rich Plasma (PRP), Exosomes (exos) therapy, In vitro Activation (IVA), Stem Cell therapy, MicroRNAs and Mitochondrial Targeting Therapies are experimental treatment strategies that focus on activating oogenesis and folliculogenesis, by upregulating natural biochemical pathways (neo-folliculogenesis) and improving ovarian microenvironment. This mini-review aims at identifying the main advantages of these approaches and exploring whether they can underpin existing assisted reproductive technologies.

show abstract